METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN Russian patent published in 2018 - IPC G01N33/52 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, specifically to oncology, and concerns a method for predicting the outcome of luminal B and three times negative breast cancer in patients who have not received chemotherapy or hormone therapy in the neoadjuvant regimen. Method comprises a biochemical study of the biological material of patients, determination of molecular biological parameters of the tumor: expression of progesterone receptors, HER-2/neu receptor expression, also, the tumor tissue and the conditionally unchanged tissue adjacent to the tumor, in which the caspase-like proteasome activity is measured by fluorometric method, is additionally examined. Then, the coefficient of caspase-like proteasome activity (CCAS) is determined, which is calculated as the ratio of the corresponding activity in the tumor tissue to activity in the unchanged tissue, and with the value of the caspase-like protease activity coefficient of CCAS more than 2.19 predict an unfavorable outcome with a high probability of developing distant metastases, and with a CCAS value of less than 2.19 predict a favorable outcome of the disease with a low probability of developing distant tumor metastases.

EFFECT: invention provides an increase in specificity and informative method for predicting the outcome of luminal B and three times negative breast cancer.

1 cl, 2 dwg, 4 ex